The Rx Recap: February 16-22

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Puzzler poll: Urticarial rash in a 9-hours-old male

Curious about diagnosing skin conditions in pediatric patients? Contemporary Pediatrics presents a challenging case of a 6-day-old man with a waxing and waning urticarial rash. His parents describe red, raised lesions that flatten, migrate, and resolve without a trace. With no other concerning symptoms and a healthy perinatal history, what could be the diagnosis? Test your clinical reasoning by selecting an answer in their poll, then return on February 24, 2025, at 10:00 PM ET for the full case breakdown, differential diagnoses, and the correct answer.

What We Want From Insurance

In Psychiatric Times, Daniel Morehead, MD, delves into the complex and often contentious relationship between the public and health insurance companies, spurred by the shocking assassination of United Healthcare CEO Brian Thompson. While some argue that insurers are scapegoats in a flawed healthcare system, Morehead presents a compelling case that the real source of public outrage is not just high costs but a pervasive sense of deception. Drawing from 2 decades of experience, he argues that patients tolerate expensive treatments when costs are clear but become enraged when faced with hidden fees, loopholes, and denied claims. Ultimately, Morehead calls for transparency, fairness, and an end to the manipulative tactics that fuel distrust in the insurance industry.

8 challenges unique to women physicians

Despite the increasing number of women entering medicine, gender disparities persist in career advancement, earnings, and leadership opportunities. Medical Economics pondered how it is that women now make up the majority of medical school applicants and enrollees, yet they remain underrepresented in top-paying specialties and leadership roles—a phenomenon known as the "leaky pipeline." Studies show that female physicians earn significantly less than their male counterparts, making an average of 74 cents for every dollar earned by men. Beyond pay gaps, women in medicine also face barriers such as implicit bias, limited mentorship, caregiving responsibilities, and workplace harassment. These challenges contribute to slower career progression and higher burnout rates. Addressing these disparities requires systemic change to create a more equitable environment for women physicians.

The Importance of Real-World Evidence in Medical Research and Drug Development

Randomized controlled trials (RCTs) are the gold standard for clinical research, but their controlled settings often limit real-world applicability. According to Applied Clinical Trials, real-world data (RWD) and real-world evidence (RWE) are transforming clinical trials, regulatory approvals, and medical practice by providing insights from everyday healthcare interactions. Regulatory bodies like the FDA are increasingly integrating RWE into drug approvals, expediting access to treatments. Despite challenges such as data quality and privacy concerns, RWE holds immense potential to improve patient care, refine medical guidelines, and democratize medical knowledge for broader accessibility.

The Global Impact of Underfunding Women’s Health

Women's health research, including menopause, remains underfunded due to social stigma and a historical male-centric approach to medicine. Experts Monica Christmas, MD, and Valentina Sartori, PhD, highlight to Managed Healthcare Executive that women spend 25% more of their lives in poorer health than men, yet menopause accounts for only 4% of pharmaceutical pipelines. Addressing these gaps could improve women's well-being and unlock over $1 trillion in global GDP. A global survey identified key menopause concerns, including nonhormonal treatments and cognitive health, emphasizing the need for more tailored research and better representation in medical studies.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.